Hook & thesis
Hims & Hers is not your average DTC play anymore. The company just reported 38% year-over-year revenue growth to $753.2 million in its most recent quarter and raised full-year guidance to $3.1-$3.3 billion. Yet the stock is trading near $29, down from a 52-week high of $65.30, with regulatory headlines dominating price action. That dislocation - strong growth on one hand and a legal overhang on the other - creates a tactical swing opportunity for disciplined traders.
My thesis: the core business - telehealth subscriptions for mental health, sexual health, dermatology and primary care - is scaling into higher-margin specialty therapies (GLP-1s, testosterone) and international revenue. If the company executes on its $3.1-$3.3 billion guidance and the GLP-1/treatment mix ramps as expected, investors should reprice HIMS closer to growth multiples. For a mid-term swing (45 trading days), the risk/reward favors a controlled long position at $29.00 with a tight stop to protect against adverse regulatory outcomes.
What Hims & Hers does and why the market should care
Hims & Hers operates a telehealth platform that connects consumers to healthcare professionals for conditions ranging from depression and anxiety to sexual health and dermatology. The platform’s appeal is simple: lower friction access to treatment, recurring subscription revenue, and product expansion into higher price-point specialty therapies. That mix is what allows the company to deliver rapid top-line growth while crossing into larger addressable markets.
Concretely, the company posted 38% revenue growth last quarter to $753.2 million and has raised FY guidance to $3.1-$3.3 billion. Those numbers indicate the business is scaling: recurring care plus higher-ticket therapies (currently approaching a $100 million annual run rate in testosterone) create upside to revenue and potentially to margins as fixed marketing and ops costs are leveraged.
Key financial and valuation framing
At the current market snapshot, market capitalization sits around $6.7 billion and enterprise value near $7.48 billion. Relevant multiples:
- Price-to-sales ~2.84.
- EV-to-sales ~3.16.
- Free cash flow recently reported around $66.9 million.
- Trailing EPS is negative, and the company shows negative ROE (-2.97%) and slightly negative ROA.
These multiples imply the market is pricing growth with caution - reasonable for a company still investing aggressively and facing legal risk. Consider that HIMS is trading roughly at 3x EV/S on a business coming off >30% top-line growth and with guidance indicating roughly $3.1-$3.3 billion of revenue this year: if growth reaccelerates via GLP-1 demand and international expansion, multiples could re-rate higher. That said, the negative earnings metrics and meaningful debt-to-equity of ~2.18 argue for conservative position sizing.
Technical and market structure notes
- Average daily volume over recent periods is ~13.1 million shares, which supports trade liquidity for active sizing.
- Short interest is material - ~58.7 million shares on the latest settlement - which can amplify moves in both directions.
- RSI sits near neutral (~45.7) and the 10/20/50 day SMA/EMA picture suggests the stock is off its recent highs but not deeply oversold.
Catalysts that could drive the trade
- GLP-1 demand tailwind: employers expected to reduce coverage in 2027 could push patients to DTC telehealth providers, increasing acquisition velocity and lifetime value.
- International expansion and the Eucalyptus acquisition - management has flagged $600 million of international revenue ambition for 2026; any early progress reports would be positive.
- Quarterly results or updated guidance that beat current targets ($3.1-$3.3B) would be a clear re-rating trigger.
- Resolution or mitigation of the FTC lawsuit and related investigations - even partial wins or narrow settlement terms would materially reduce the regulatory overhang.
Trade plan - actionable and time-boxed
Entry: Buy at $29.00.
Stop-loss: $25.50 - placed to limit downside if regulatory rulings or an earnings miss drive a sustained sell-off.
Target: $38.00 - a realistic re-rating to a higher multiple as operational momentum and GLP-1 demand reassert themselves.
This is a mid-term swing: hold for up to 45 trading days (mid term - 45 trading days). Why 45 days? That window covers the next quarterly cadence and gives time for catalysts - product ramp commentary, investor updates on international rollouts, or preliminary legal developments - to materialize. If the stock marches steadily toward the target, consider scaling out in two tranches: half at $34 and the remainder at $38 to lock in gains while leaving room for further upside.
Position sizing and risk control
Given the mixed risk profile - strong growth but sizeable legal exposure and negative earnings - this trade should be sized conservatively relative to portfolio capital. Use the $25.50 stop to cap downside and avoid adding into unexpected regulatory announcements.
Risks and counterarguments
- Regulatory/legal risk: The FTC lawsuit alleging deceptive data and billing practices and multiple law-firm investigations present principal downside. An adverse ruling or large settlement could materially depress revenue and margins.
- Privacy and advertising impact: Allegations of sharing sensitive health information with third-party advertisers may force changes to acquisition channels and increase CAC, harming unit economics.
- Margin compression from product mix: Expansion into testosterone and peptides can add revenue but potentially compress gross margins if these therapies have higher fulfillment or medical oversight costs.
- Balance sheet and leverage: Debt-to-equity ~2.18 and modest cash on hand mean the company has less flexibility than a net-cash growth company; this raises risk if revenue growth slows.
- Execution risk: International expansion and integration of acquisitions (Eucalyptus) may take longer than expected, delaying the revenue and margin benefits management expects.
Counterargument: The legal overhang and privacy allegations are not minor. If the FTC or states secure a precedent-setting judgment or if significant consumer redress is required, the business model could be fundamentally impaired, making multiples much lower despite growth. That justifies a tight stop and conservative sizing for this trade.
What would change my mind
- I would become more bullish (add or widen targets) if HIMS posts a clear beat-and-raise quarter, demonstrates improving unit economics on GLP-1 and specialty therapies, and the company announces a narrow settlement or a favorable early legal ruling that meaningfully reduces contingency exposure.
- I would step aside or flip bearish if the company lowers guidance, if a regulatory decision forces a material pause on key acquisition channels, or if the FTC wins a judgment that imposes multi-hundred-million-dollar damages or injunctive remedies that restrict operations.
Conclusion
Hims & Hers sits at the intersection of rapid digital healthcare adoption and heavy regulatory scrutiny. For traders willing to accept elevated legal risk, the current price dislocation offers an asymmetric mid-term swing: solid topline growth and product expansion on one side, and headline-driven downside on the other. The recommended plan - buy $29.00, stop $25.50, target $38.00, hold up to 45 trading days - attempts to capture upside from operational catalysts while limiting exposure to a binary regulatory outcome.
Trade with discipline. If regulation recedes or operational momentum continues, HIMS could re-rate quickly. If the legal overhang worsens, respect the stop and preserve capital.